- Home
- BBIO vs NCLH Comparison
BBIO vs NCLH Comparison
Compare BBIO & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- NCLH
- Stock Information
- Founded
- BBIO 2015
- NCLH 1966
- Country
- BBIO United States
- NCLH United States
- Employees
- BBIO N/A
- NCLH N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- NCLH Marine Transportation
- Sector
- BBIO Health Care
- NCLH Consumer Discretionary
- Exchange
- BBIO Nasdaq
- NCLH Nasdaq
- Market Cap
- BBIO 10.4B
- NCLH 10.7B
- IPO Year
- BBIO 2019
- NCLH 2013
- Fundamental
- Price
- BBIO $61.73
- NCLH $19.12
- Analyst Decision
- BBIO Strong Buy
- NCLH Buy
- Analyst Count
- BBIO 18
- NCLH 17
- Target Price
- BBIO $74.28
- NCLH $29.65
- AVG Volume (30 Days)
- BBIO 2.7M
- NCLH 19.1M
- Earning Date
- BBIO 10-29-2025
- NCLH 11-04-2025
- Dividend Yield
- BBIO N/A
- NCLH N/A
- EPS Growth
- BBIO N/A
- NCLH 11.76
- EPS
- BBIO N/A
- NCLH 1.40
- Revenue
- BBIO $353,780,000.00
- NCLH $9,692,558,000.00
- Revenue This Year
- BBIO $123.32
- NCLH $8.20
- Revenue Next Year
- BBIO $73.46
- NCLH $10.58
- P/E Ratio
- BBIO N/A
- NCLH $13.64
- Revenue Growth
- BBIO 62.46
- NCLH 3.59
- 52 Week Low
- BBIO $21.72
- NCLH $14.21
- 52 Week High
- BBIO $69.48
- NCLH $29.29
- Technical
- Relative Strength Index (RSI)
- BBIO 59.65
- NCLH 27.78
- Support Level
- BBIO $60.23
- NCLH $18.07
- Resistance Level
- BBIO $64.44
- NCLH $22.76
- Average True Range (ATR)
- BBIO 3.05
- NCLH 0.80
- MACD
- BBIO 0.06
- NCLH -0.45
- Stochastic Oscillator
- BBIO 53.68
- NCLH 16.49
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.